Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P606 | DOI: 10.1530/endoabs.56.P606

ECE2018 Poster Presentations: Diabetes, Obesity and Metabolism Obesity (78 abstracts)

Differences in percentage of weight loss and secondary effects after one and two months of treatment with liraglutide versus naltrexone/bupropion

Beatriz Voltas Arribas , Carlos Sánchez Juan , Juan Carlos Ferrer García , Ana Artero Fullana , Pablo Sanz Revert , Cristian Marco Alacid & Mario López Merseguer


Hospital General de Valencia, Valencia, Spain.


Introduction: Obesity is one of the most prevalent health problems in our society. The marketing of Liraglutide and the Naltrexone/Bupropion combination has been given the green light.

Objectives: To analyze the differences in a series of 19 patients assigned to treatment with Liraglutide or Naltrexone/Bupropion.

Material and methods: A descriptive analysis was carried out using Stata. 19 patients were included, 9 were treated with Liraglutide and 10 with Naltrexone/Bupropion. We analyzed the percentage of weight loss and side effects at one month and two months after treatment initiation.

Results: Of the 9 patients included in the Liraglutide arm, 2 were male and 7 were female, with a mean age of 56.22 and a mean BMI of 41.35. From the Naltrexone/Bupropion group, 5 male and 5 female participants, with a mean age of 52.90 and an initial BMI of 34.40. After one month of treatment, a % weight loss of 3.81 was observed for the Liraglutide group versus 1.06 for Naltrexone/Bupropion (difference of means 2.75). After two months, a 7.51% weight loss was observed for Liraglutide versus 0.12% for Naltrexone/Bupropion (mean difference 7.40), the latter being statistically significant. 77.8% of patients treated with Liraglutide developed secondary side effects at the first month (28.57% at the second visit), only one patient withdrew from taking the drug. In the Naltrexone/Bupropion group, side effects were observed in 20% with two dropouts for this reason (another 4 abandoned the treatment for other reasons). Regarding the dosage of Liraglutide per month, 11% of Liraglutide 1.2 mg, 33% 1.8 mg, 33% 2.4 mg, 22% 3 mg. At two months, 43.86% 1.8 mg and 57.14% 3 mg.

Conclusions: In our clinical practice we observed a greater weight loss % in the Liraglutide group, especially at two months of treatment. The number of negative side effects was greater for Liraglutide, primarily in the first month, with a higher abandonment rate for Naltrexone/Bupropion.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.